Skip to main content
Full access
CLINICAL SYNTHESIS
Published Online: 1 October 2010

New Vistas in the Management of Treatment-Refractory Psychiatric Disorders: Genomics and Personalized Medicine

Abstract

To date, most therapies of treatment-refractory psychiatric disorders involve modifications of existing pharmacological treatments and/or cognitive therapies. However, many of these strategies are unable to bring these disorders into remission; therefore, a substantial number of patients with severe psychiatric disorders continue to have marked functional limitations. Newer therapies involve novel pharmacological approaches and novel psychotherapies as well as altering neuronal circuitry via techniques such as deep brain or transcranial magnetic stimulation; however, these newer therapies are also not completely efficacious. With the 10-year anniversary of the sequencing of the human genome, genetic analysis emerges as an important approach in assessing therapeutic response. In this review, the authors will examine the current knowledge of gene and environmental interactions in treatment response for a subset of psychiatric diseases.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

History

Published online: 1 October 2010
Published in print: Fall 2010

Authors

Affiliations

Amanda J. Myers, Ph.D.

Notes

Address correspondence to Charles B. Nemeroff, M.D., Ph.D., Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Clinical Research Building, 1120. NW 14th Street, Room 1455 (D-21), Miami, FL 33136; e-mail: [email protected]

Funding Information

CME Disclosure
Amanda J. Myers, Ph.D., Laboratory of Functional Neurogenomics, University of Miami Miller School of Medicine, Miami, FL
Dr. Myers reports no competing interests.
Charles B. Nemeroff, M.D., Ph.D., Leonard M. Miller Professor and Chairman, Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL.
Dr. Nemeroff is a member of the Scientific Advisory Board of AstraZeneca and PharmaNeuroBoost. He holds equity and/or stock options in Corcept Therapeutics, CeNeRx, Reevax Pharma, PharmaNeuroBoost, and NovaDel Pharma.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share